Skip to content
In English |
En español
Search
Clinical Trials Search Results
Page Options
E-Mail This Search
Clinical Trial Questions?
Get Help:
1-800-4-CANCER
Quick Links
Help Using the NCI Clinical Trials Search Form
Educational Materials About Clinical Trials
About NCI's Cancer Clinical Trials Registry
Dictionary of Cancer Terms
NCI Drug Dictionary
View Content for:
Patients
Health Professionals
Display:
Title
Description with:
Locations
Eligibility
Full Trial Description
Custom
Results 1-11 of 11 for your search:
Cancer Type/Condition:
Childhood germ cell tumor
Stage/Subtype:
recurrent childhood germ cell tumor
Country:
U.S.A.
Trial Type:
Treatment
Trial Status:
Active
Hide Search Criteria
Show Search Criteria
Help with Results
Select All on Page
Sort by:
Phase of Trial
Title
Type of Trial
Status of Trial
Age Range
Sponsor of Trial
Protocol IDs
Show
10
25
50
100
200
Results per Page
1.
Tandem Peripheral Blood Stem Cell (PBSC) Rescue for High Risk Solid Tumors
Phase:
Phase II, Phase I
Type:
Treatment
Status:
Active
Age:
21 and under
Sponsor:
Other
Protocol IDs:
BMT 0499 Solid
, NCT00179816
2.
Evaluation of Single Session Stereotactic Body Radiotherapy
Phase:
Phase II, Phase I
Type:
Treatment
Status:
Active
Age:
Not specified
Sponsor:
Other
Protocol IDs:
2005-0445
, NCT00492817
3.
Evaluation of a Novel CT-On-Rails or Trilogy Stereotactic Spine Radiotherapy System (SSRS)
Phase:
Phase II, Phase I
Type:
Supportive care, Treatment
Status:
Active
Age:
Not specified
Sponsor:
Other
Protocol IDs:
ID02-446
, NCT00508443
4.
Dasatinib, Ifosfamide, Carboplatin, and Etoposide in Treating Young Patients With Metastatic or Recurrent Malignant Solid Tumors
Phase:
Phase II, Phase I
Type:
Biomarker/Laboratory analysis, Treatment
Status:
Active
Age:
1 to 25
Sponsor:
NCI, Pharmaceutical / Industry
Protocol IDs:
CHNMC-07053
, 07053, CA180 121, NCT00788125
5.
Melphalan, Carboplatin, and Sodium Thiosulfate for Patients With Central Nervous System (CNS) Embryonal or Germ Cell Tumors
Phase:
Phase II, Phase I
Type:
Treatment
Status:
Active
Age:
1 to 30
Sponsor:
Other
Protocol IDs:
OHSU-5056
, OHSU SOL-08131-L, NCT00983398
6.
Combination Chemotherapy in Treating Young Patients With Recurrent or Resistant Malignant Germ Cell Tumors
Phase:
Phase II
Type:
Treatment
Status:
Active
Age:
Under 21 at original diagnosis
Sponsor:
NCI
Protocol IDs:
COG-AGCT0521
, AGCT0521, NCT00467051
7.
High-dose Chemotherapy for Poor-prognosis Relapsed Germ-Cell Tumors
Phase:
Phase II
Type:
Treatment
Status:
Active
Age:
12 to 65
Sponsor:
Other
Protocol IDs:
2008-0378
, NCT00936936
8.
ARQ 197 for Subjects With Relapsed or Refractory Germ Cell Tumors
Phase:
Phase II
Type:
Treatment
Status:
Active
Age:
16 and over
Sponsor:
Pharmaceutical / Industry
Protocol IDs:
ARQ 197-A-U251
, NCT01055067
9.
Ixabepilone in Treating Young Patients With Solid Tumors or Leukemia That Haven't Responded to Therapy
Phase:
Phase I
Type:
Treatment
Status:
Active
Age:
2 to 21
Sponsor:
NCI
Protocol IDs:
NCI-02-C-0031
, 02-C-0031, 5425, NCI-5425, NCT00030108
10.
Cediranib in Treating Young Patients With Refractory or Recurrent Solid Tumors or Acute Myeloid Leukemia
Phase:
Phase I
Type:
Biomarker/Laboratory analysis, Treatment
Status:
Active
Age:
2 to 18
Sponsor:
NCI, Pharmaceutical / Industry
Protocol IDs:
NCI-06-C-0152
, NCI-P6571, NCT00354848, ZENECA-D8480C00016
11.
Busulfan, Melphalan, Topotecan, and a Stem Cell Transplant in Treating Patients With Newly Diagnosed or Relapsed Solid Tumor
Phase:
No phase specified
Type:
Biomarker/Laboratory analysis, Treatment
Status:
Active
Age:
6 months to 40
Sponsor:
NCI
Protocol IDs:
CHNMC-03112
, 03112, NCT00638898
Select All on Page
Help with Results
